KRRO vs NTLA
KRRO: Korro Bio is a clinical-stage biotechnology company developing genetic medicines via a proprietary oligonucleotide platform, currently focused on treating alpha-1 antitrypsin deficiency. NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
Side-by-side fundamentals
| Metric | KRRO | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $11.70 | $11.13 | |
| Market cap as of 2026-07-23 | $168M | $1.6B | |
| PEG as of 2026-07-23 | -0.04 | n/a | |
| Net margin as of 2026-07-23 | -1834.5% | -597.0% | NTLA higher |
| Gross margin as of 2026-07-23 | +44.7% | n/a | |
| Operating margin as of 2026-07-23 | -1906.4% | -636.6% | NTLA higher |
| ROE as of 2026-07-23 | -117.9% | -57.3% | NTLA higher |
| ROA as of 2026-07-23 | -71.0% | -46.1% | NTLA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -20.3% | +45.0% | NTLA higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.1% | |
| Beta as of 2026-07-23 | 3.05 | 1.78 | |
| 1-year return as of 2026-07-22 close | -10.3% | -17.5% | KRRO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.